Original language | English (US) |
---|---|
Pages (from-to) | 705-713 |
Number of pages | 9 |
Journal | Neurology |
Volume | 93 |
Issue number | 16 |
DOIs | |
State | Published - Oct 15 2019 |
ASJC Scopus subject areas
- Clinical Neurology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Neurology, Vol. 93, No. 16, 15.10.2019, p. 705-713.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Quality improvement in neurology
T2 - Mild cognitive impairment quality measurement set
AU - Foster, Norman L.
AU - Bondi, Mark W.
AU - Das, Rohit
AU - Foss, Mary
AU - Hershey, Linda A.
AU - Koh, Steve
AU - Logan, Rebecca
AU - Poole, Carol
AU - Shega, Joseph W.
AU - Sood, Ajay
AU - Thothala, Niranjan
AU - Wicklund, Meredith
AU - Yu, Melissa
AU - Bennett, Amy
AU - Wang, David
N1 - Funding Information: N. Foster reports receiving grant support from the NIH, the June Morris Trust, and Rodney and Carolyn Brady Fund, and research funding from GE Health, AbbVie, Biogen, Suven, and Lilly Pharmaceuticals. Dr. Foster serves as a consultant for AbbVie and is CEO and co-owner of Proactive Memory Services, Inc. M. Bondi reports receiving grant support from the NIH, serving as a consultant for Eisai, Novartis, and Roche, and receiving royalties from Oxford University Press. R. Das reports research funding from Eisai, consulting with law firms and Neurotech EEG, and prior speakers’ bureau with LivaNova. M. Foss reports no disclosures relevant to the manuscript. L. Hershey reports she is author of the annual memory loss review for MedLink Neurology, has received royalties from MedLink Corporation and American College of Physicians, and has served on the Network of Experts for the FDA. S. Koh reports no disclosures relevant to the manuscript. R. Logan reports volunteering for the Alzheimer’s Association and serving on their Speakers Bureau and current participation in National Institute of Aging and Eli Lilly and Company research projects. C. Poole and J. Shega report no disclosures relevant to the manuscript. A. Sood has received research support from Takeda Inc, Roche, Merck, Eli Lilly, Neurotrope, Novartis, Eisai, Avanir, and Biogen; received compensation for talks for Piramal; and served as Site PI for IDEAS study. N. Thothala reports no disclosures relevant to the manuscript. M. Wicklund receives research support from the Florida Department of Health Ed and Ethel Moore Alzheimer’s Disease Research Program, IDEAS, and Novartis. M. Yu reports no disclosures relevant to the manuscript. Q. Bennett is an employee of the American Academy of Neurology. D. Wang reports no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.
PY - 2019/10/15
Y1 - 2019/10/15
UR - http://www.scopus.com/inward/record.url?scp=85073184410&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073184410&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000008259
DO - 10.1212/WNL.0000000000008259
M3 - Article
C2 - 31534026
AN - SCOPUS:85073184410
SN - 0028-3878
VL - 93
SP - 705
EP - 713
JO - Neurology
JF - Neurology
IS - 16
ER -